Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.22.4
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents [note 7] $ 24,771 $ 43,022
Grant receivable [note 4] 105 153
Prepaid expenses and other assets 2,454 1,419
Total current assets 27,330 44,594
Restricted cash and other assets [note 7 and note 8] 66 183
Right-of-use assets [note 12] 123 64
License agreement [note 5 and note 6] 1,418 1,641
Goodwill [note 5] 1,034 1,034
Total assets 29,971 47,516
Current liabilities:    
Accounts payable 1,660 841
Accrued liabilities other 403 348
Accrued clinical liabilities 1,729 1,352
Accrued compensation 1,678 1,940
Current portion of long-term obligations [note 12] 58 69
Convertible debt [note 7 and note 9] 16,071  
Total current liabilities 21,599 4,550
Convertible debt [note 7 and 9]   14,920
Long-term obligations [note 12] 69 4
Total liabilities 21,668 19,474
Commitments and contingencies [note 12]
Stockholders' equity:    
Common stock, $0.001 par value, 150,000,000 shares authorized, 17,897,029 and 9,453,542 issued and outstanding at December 31, 2022 and December 31, 2021, respectively. 87 79
Additional paid-in capital 144,148 121,545
Accumulated deficit (135,936) (93,586)
Accumulated other comprehensive income 4 4
Total stockholders' equity 8,303 28,042
Total liabilities and stockholders' equity 29,971 47,516
Series A Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value